FDA cites Dura for insufficient information in its Nov. 4 press release on a "not approvable" letter for its albuterol AlSpiros inhaler. "The overall promotional message of the press release misleadingly minimizes the fact that Dura must conduct a completely new clinical trial program for the redesigned to-be-marketed product," the FDA letter states, emphasizing that "these clinical trials (12 weeks and one-year open label) must be conducted prior" to FDA's reconsideration of the product. The agency requested that Dura specifically ask for the removal of the press release from the PRNewswire website
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth